TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Test-to-Reference Measurement Pairs with ARD ≤15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in volume of distribution (Vt) in different brain regions for [11C]-PBR28 PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in esophageal wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in Left Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events related to ECM accumulation
Endpoint domain: Adverse events/effects
Primary endpoint: IGF-1 level in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: daily clearance volume of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serial changes in sputum coloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: chest X-ray improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sleep time measured using polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Total sleep time measured using wrist actigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Sleep measurement using Thai-version Richards Campbell Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Structural and functional connectives in brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax (Maximum Plasma Concentration) of FTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time to Reach Maximum Drug Concentration in Blood) of FTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time (t) of the Last Quantifiable Concentration) of FTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score based on 28 joint count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evolution of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30-Day Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Antioxidant enzyme activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Baseline Step Length Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Action Research Arm Test (ARAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Upper Extremity Component of the Fugl-Meyer Scale (UEFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a stated preference for either study medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraoperative Blood Transfusion Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Grade III or more mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative incidence of failures
Endpoint domain: Mortality/survival
Primary endpoint: Number of mature adipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Asthma Control Test (ACT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: School readiness percentage
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child executive functioning tasks composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of epidermal nerve fiber regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Haemostatic Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of administering CD8+ HIV-specific CTL clones with IL-2
Endpoint domain: Adverse events/effects
Primary endpoint: In vivo persistence and function of CD8+ HIV-specific CTL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Shoulder Rating Questionnaire (SRQ) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in brain activity related to central motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients with HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of errors on trained ADL tasks at post-training phase compared to baseline phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of old/new errors on trained ADL tasks at post-training phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of errors (target errors, distractor errors, conflicting errors) on trained ADL tasks with novel executive/monitoring requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with reduced MRI volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression compared to the previous therapy lane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CRE eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Sustained Attention to Response Task (SART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Working Memory Task with Affective Distraction (WMDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and clinical benefit of lymphoablation followed by autologous HSCT rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Anti-tumor Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Asthma Control overall change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average importance of patient reported outcomes (PRO) after first Delphi survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average importance of patient reported outcomes (PRO) after second Delphi survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge, attitude and practice regarding Post Exposure Prophylaxis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Response (Complete and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of SAEs and treatment-related severe AEs
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI response in the hypothalamus and brainstem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI response in the whole brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in urinary metabolites excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraabdominal Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiety response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with PiB positive PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Deep Vein Thrombosis (DVT) and Non fatal Pulmonary Embolism (PE) and Death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Change in 24h pad testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Survey Responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Reduction in Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain Intensity at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in BODE-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nystagmus detection sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size and Condition of the Appendix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of diagnosis of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of diagnosis of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With American College of Rheumatology-ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp-Genant Score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Physical Function as Measured by the Area Under the Curve (AUC) for the Change From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 52
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cmax of Itacitinib When Administered With Corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate up to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease control at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in driving pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sphincter preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic accuracy of imaging biomarkers for liver fibrosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with a titer greater than 1:32 or greater than 4-fold increase in titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Global Impressions I (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Weekly Average Number of Cluster Headache Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve (AUC)(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in recent use of any violence at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in recent use of any violence at 9 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of life assessed by EQ-5D-5L Euroquol questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nasal lengths in millimeters before and after correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with migraine
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: HIV disclosure rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of the intervention as assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: gemcitabine and difluorodeoxyuridine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gemcitabine triphosphate concentration in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident of clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients experiencing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insufficient physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Advanced Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proactive cognitive control composite behavioral score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in reactive cognitive control composite behavioral score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in proactive cognitive control composite brain imaging activation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in reactive cognitive control composite brain imaging activation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pain-related Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of daily administration of amplitude-modulated electromagnetic fields
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of thromboembolic event based on the CHA2DS2-VASc score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Seroprotected Subjects Against Anti-Hepatitis B Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects for Anti-polyribosyl-ribitol Phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall survival at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Force Exerted on a Fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Values of hematological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of hematological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to Clozapine Patient Monitoring System
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical tolerability of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in height of fat bulging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of Lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial pressure (MAP in mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO2 in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Antisocial Behavior Inclinations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Pins Inserted Into a Virtual Voodoo Doll
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching fasting SMPG ≤5.6 mmol/L without nocturnal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Change From Baseline in Total Symptom Score (TSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hip related self-reports of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical activity during a period of 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Physician's Assessment of Disease Activity Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Tender Joints Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Swollen Joints Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 of Rapidly Administered Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completely remission (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Periprocedural Stroke, Myocardial Infarction, or Death
Endpoint domain: Mortality/survival
Primary endpoint: Time to SpO2 of 92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in HADS-A score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of time intragastric pH > 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distinction between progressive tumor and treatment related effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall survival at six months
Endpoint domain: Mortality/survival
Primary endpoint: FASH questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Study Endpoint in Mean Weekly Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lapse of time from arrival in France to HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lapse of time from arrival in France to hepatitis B testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lapse of time from HIV diagnostic to access to care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lapse of time from hepatitis B diagnostic to access to care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bronchial Secretion Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in number of Intermittent hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in the proliferation of normal breast epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Global Neurocognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Domain-Specific Neurocognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ACE2 receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory Function Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Thickness of bronchial wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Thermotolerant coliforms in household drinking water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjective Lens Wear Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in conditioned pain modulation (CPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with prescribed medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Videocystometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: response rate including degree of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steroid sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assessment of problems or side effects or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Study product-related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Biopsy procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Injection procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Medication Specific Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spleen Volume Reduction of greater than or equal to 35% (SVR35)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of HSCT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention